Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 82 entries
Sorted by: Best Match Show Resources per page
The clinical research mission of dental colleges.

Dental journal

Taintor JF, Biesterfeld RC.
PMID: 283014
Dent J. 1979 Jan;45(1):26-7.

No abstract available.

Cite
Taintor JF, Biesterfeld RC. The clinical research mission of dental colleges. Dent J. 1979;45(1):26-7
Taintor, J. F., & Biesterfeld, R. C. (1979). The clinical research mission of dental colleges. Dental journal, 45(1), 26-7.
Taintor, J F, and Biesterfeld, R C. "The clinical research mission of dental colleges." Dental journal vol. 45,1 (1979): 26-7.
Taintor JF, Biesterfeld RC. The clinical research mission of dental colleges. Dent J. 1979 Jan;45(1):26-7. PMID: 283014.
Copy Download .nbib Format: NLM
Beginning and continuing.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry

Taintor Z.
PMID: 24442970
Acad Psychiatry. 1989 Mar;13(1):1-2. doi: 10.1007/BF03341834.

No abstract available.

Cite
Taintor Z. Beginning and continuing. Acad Psychiatry. 1989;13(1):1-2doi: 10.1007/BF03341834.
Taintor, Z. (1989). Beginning and continuing. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry, 13(1), 1-2. https://doi.org/10.1007/BF03341834
Taintor, Z. "Beginning and continuing." Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry vol. 13,1 (1989): 1-2. doi: https://doi.org/10.1007/BF03341834
Taintor Z. Beginning and continuing. Acad Psychiatry. 1989 Mar;13(1):1-2. doi: 10.1007/BF03341834. PMID: 24442970.
Copy Download .nbib Format: NLM
Putting the brakes on CTLA-4 inhibition in lung cancer?.

Translational lung cancer research

Mooradian MJ, Gainor JF.
PMID: 29531902
Transl Lung Cancer Res. 2018 Feb;7:S35-S38. doi: 10.21037/tlcr.2018.01.05.

No abstract available.

Cite
Mooradian MJ, Gainor JF. Putting the brakes on CTLA-4 inhibition in lung cancer?. Transl Lung Cancer Res. 2018;7:S35-S38doi: 10.21037/tlcr.2018.01.05.
Mooradian, M. J., & Gainor, J. F. (2018). Putting the brakes on CTLA-4 inhibition in lung cancer?. Translational lung cancer research, 7S35-S38. https://doi.org/10.21037/tlcr.2018.01.05
Mooradian, Meghan J, and Gainor, Justin F. "Putting the brakes on CTLA-4 inhibition in lung cancer?." Translational lung cancer research vol. 7 (2018): S35-S38. doi: https://doi.org/10.21037/tlcr.2018.01.05
Mooradian MJ, Gainor JF. Putting the brakes on CTLA-4 inhibition in lung cancer?. Transl Lung Cancer Res. 2018 Feb;7:S35-S38. doi: 10.21037/tlcr.2018.01.05. PMID: 29531902; PMCID: PMC5835619.
Copy Download .nbib Format: NLM
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.

Cancer cell

Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ.
PMID: 34990570
Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05.

Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses...

Cite
Naranbhai V, St Denis KJ, Lam EC, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;40(1):103-108.e2doi: 10.1016/j.ccell.2021.12.002.
Naranbhai, V., St Denis, K. J., Lam, E. C., Ofoman, O., Garcia-Beltran, W. F., Mairena, C. B., Bhan, A. K., Gainor, J. F., Balazs, A. B., Iafrate, A. J. (2022). Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer cell, 40(1), 103-108.e2. https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai, Vivek, et al. "Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer." Cancer cell vol. 40,1 (2022): 103-108.e2. doi: https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05. PMID: 34990570; PMCID: PMC8730528.
Copy Download .nbib Format: NLM
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.

Cancer cell

Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ.
PMID: 34990570
Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05.

Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses...

Cite
Naranbhai V, St Denis KJ, Lam EC, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;40(1):103-108.e2doi: 10.1016/j.ccell.2021.12.002.
Naranbhai, V., St Denis, K. J., Lam, E. C., Ofoman, O., Garcia-Beltran, W. F., Mairena, C. B., Bhan, A. K., Gainor, J. F., Balazs, A. B., Iafrate, A. J. (2022). Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer cell, 40(1), 103-108.e2. https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai, Vivek, et al. "Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer." Cancer cell vol. 40,1 (2022): 103-108.e2. doi: https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05. PMID: 34990570; PMCID: PMC8730528.
Copy Download .nbib Format: NLM
Intracranial Efficacy of Selpercatinib in .

Clinical cancer research : an official journal of the American Association for Cancer Research

Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A.
PMID: 34088726
Clin Cancer Res. 2021 Aug 01;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 04.

PURPOSE: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for PATIENTS AND METHODS: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RESULTS: Eighty patients with NSCLC...

Cite
Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial Efficacy of Selpercatinib in . Clin Cancer Res. 2021;27(15):4160-4167doi: 10.1158/1078-0432.CCR-21-0800.
Subbiah, V., Gainor, J. F., Oxnard, G. R., Tan, D. S. W., Owen, D. H., Cho, B. C., Loong, H. H., McCoach, C. E., Weiss, J., Kim, Y. J., Bazhenova, L., Park, K., Daga, H., Besse, B., Gautschi, O., Rolfo, C., Zhu, E. Y., Kherani, J. F., Huang, X., Kang, S., & Drilon, A. (2021). Intracranial Efficacy of Selpercatinib in . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4160-4167. https://doi.org/10.1158/1078-0432.CCR-21-0800
Subbiah, Vivek, et al. "Intracranial Efficacy of Selpercatinib in ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4160-4167. doi: https://doi.org/10.1158/1078-0432.CCR-21-0800
Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in . Clin Cancer Res. 2021 Aug 01;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 04. PMID: 34088726; PMCID: PMC8447251.
Copy Download .nbib Format: NLM
Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study.

The British journal of ophthalmology

Fraser-Bell S, Kang HK, Mitchell P, Arnold JJ, Tainton J, Simonyi S.
PMID: 34433549
Br J Ophthalmol. 2021 Aug 25; doi: 10.1136/bjophthalmol-2021-319070. Epub 2021 Aug 25.

AIM: To evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME).METHODS: The open-label, prospective, phase 4, real-world study included pseudophakic eyes and...

Cite
Fraser-Bell S, Kang HK, Mitchell P, et al. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. Br J Ophthalmol. 2021;doi: 10.1136/bjophthalmol-2021-319070.
Fraser-Bell, S., Kang, H. K., Mitchell, P., Arnold, J. J., Tainton, J., & Simonyi, S. (2021). Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. The British journal of ophthalmology, . https://doi.org/10.1136/bjophthalmol-2021-319070
Fraser-Bell, Samantha, et al. "Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study." The British journal of ophthalmology vol. (2021). doi: https://doi.org/10.1136/bjophthalmol-2021-319070
Fraser-Bell S, Kang HK, Mitchell P, Arnold JJ, Tainton J, Simonyi S. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. Br J Ophthalmol. 2021 Aug 25; doi: 10.1136/bjophthalmol-2021-319070. Epub 2021 Aug 25. PMID: 34433549.
Copy Download .nbib Format: NLM
Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H.
PMID: 34838892
Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25.

The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody...

Cite
Bowes CL, Naranbhai V, St Denis KJ, et al. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021;166:88-91doi: 10.1016/j.radonc.2021.11.012.
Bowes, C. L., Naranbhai, V., St Denis, K. J., Lam, E. C., Bertaux, B., Keane, F. K., Khandekar, M. J., Balazs, A. B., Iafrate, J. A., Gainor, J. F., & Willers, H. (2021). Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16688-91. https://doi.org/10.1016/j.radonc.2021.11.012
Bowes, Cynthia L, et al. "Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 88-91. doi: https://doi.org/10.1016/j.radonc.2021.11.012
Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25. PMID: 34838892; PMCID: PMC8613981.
Copy Download .nbib Format: NLM
Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Shepherd DJ, Tabb ES, Kunitoki K, Zhang ML, Kem M, Barth J, Qualls DA, Mooradian MJ, Gainor JF, Mino-Kenudson M, Hung YP.
PMID: 34880448
Mod Pathol. 2021 Dec 08; doi: 10.1038/s41379-021-00974-9. Epub 2021 Dec 08.

Lymphocyte-activation gene 3 (LAG-3) modulates the tumor microenvironment through immunosuppressive effects. Its associations with clinicopathologic parameters and prognostic significance in non-small-cell lung carcinomas remain unclear. We examined LAG-3 expression in 368 resected non-small-cell lung carcinomas (including 218 adenocarcinomas and...

Cite
Shepherd DJ, Tabb ES, Kunitoki K, et al. Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Mod Pathol. 2021;doi: 10.1038/s41379-021-00974-9.
Shepherd, D. J., Tabb, E. S., Kunitoki, K., Zhang, M. L., Kem, M., Barth, J., Qualls, D. A., Mooradian, M. J., Gainor, J. F., Mino-Kenudson, M., & Hung, Y. P. (2021). Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, . https://doi.org/10.1038/s41379-021-00974-9
Shepherd, Daniel J, et al. "Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. (2021). doi: https://doi.org/10.1038/s41379-021-00974-9
Shepherd DJ, Tabb ES, Kunitoki K, Zhang ML, Kem M, Barth J, Qualls DA, Mooradian MJ, Gainor JF, Mino-Kenudson M, Hung YP. Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Mod Pathol. 2021 Dec 08; doi: 10.1038/s41379-021-00974-9. Epub 2021 Dec 08. PMID: 34880448.
Copy Download .nbib Format: NLM
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.

Cancer cell

Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ.
PMID: 34990570
Cancer Cell. 2022 Jan 05; doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05.

Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses...

Cite
Naranbhai V, St Denis KJ, Lam EC, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;doi: 10.1016/j.ccell.2021.12.002.
Naranbhai, V., St Denis, K. J., Lam, E. C., Ofoman, O., Garcia-Beltran, W. F., Mairena, C. B., Bhan, A. K., Gainor, J. F., Balazs, A. B., Iafrate, A. J. (2022). Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer cell, . https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai, Vivek, et al. "Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer." Cancer cell vol. (2022). doi: https://doi.org/10.1016/j.ccell.2021.12.002
Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, Bhan AK, Gainor JF, Balazs AB, Iafrate AJ. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022 Jan 05; doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 05. PMID: 34990570.
Copy Download .nbib Format: NLM
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.

ESMO open

Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF.
PMID: 34896762
ESMO Open. 2021 Dec 09;7(1):100342. doi: 10.1016/j.esmoop.2021.100342. Epub 2021 Dec 09.

BACKGROUND: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is highly effective in advanced ALK-rearranged non-small-cell lung cancer and represents a standard first-line therapy. New strategies are needed, however, to delay resistance. We conducted a phase...

Cite
Lin JJ, Muzikansky A, Kennedy E, et al. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2021;7(1):100342doi: 10.1016/j.esmoop.2021.100342.
Lin, J. J., Muzikansky, A., Kennedy, E., Kuberski, H., Stober, L. L., Wanat, A. C., Azzoli, C. G., Lennes, I., Sequist, L. V., Dagogo-Jack, I., Shaw, A. T., & Gainor, J. F. (2021). Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO open, 7(1), 100342. https://doi.org/10.1016/j.esmoop.2021.100342
Lin, J J, et al. "Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study." ESMO open vol. 7,1 (2021): 100342. doi: https://doi.org/10.1016/j.esmoop.2021.100342
Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2021 Dec 09;7(1):100342. doi: 10.1016/j.esmoop.2021.100342. Epub 2021 Dec 09. PMID: 34896762; PMCID: PMC8666648.
Copy Download .nbib Format: NLM
Energy, transport, and consumption in the Industrial Revolution.

The Behavioral and brain sciences

Tainter JA, Taylor TG.
PMID: 31744564
Behav Brain Sci. 2019 Nov 20;42:e209. doi: 10.1017/S0140525X19000153.

We question Baumard's underlying assumption that humans have a propensity to innovate. Affordable transportation and energy underpinned the Industrial Revolution, making mass production/consumption possible. Although we cannot accept Baumard's thesis on the Industrial Revolution, it may help explain why...

Cite
Tainter JA, Taylor TG. Energy, transport, and consumption in the Industrial Revolution. Behav Brain Sci. 2019;42:e209doi: 10.1017/S0140525X19000153.
Tainter, J. A., & Taylor, T. G. (2019). Energy, transport, and consumption in the Industrial Revolution. The Behavioral and brain sciences, 42e209. https://doi.org/10.1017/S0140525X19000153
Tainter, Joseph A, and Taylor, Temis G. "Energy, transport, and consumption in the Industrial Revolution." The Behavioral and brain sciences vol. 42 (2019): e209. doi: https://doi.org/10.1017/S0140525X19000153
Tainter JA, Taylor TG. Energy, transport, and consumption in the Industrial Revolution. Behav Brain Sci. 2019 Nov 20;42:e209. doi: 10.1017/S0140525X19000153. PMID: 31744564.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 82 entries